February 18, 2026
The Strange Case of Dr. Jekyll and Mr. Hyde might make for a great read, but it’s far less fun when markets and the C> sector act like it’s their blueprint
Minutes and coming econs, waiting for Fed minutes from the policymakers’ January and the (PCE) personal consumption expenditure price index reading due on Friday
Pre-open Signals: 3 Positive and 1 Negative; if you understand probabilities, the inevitable is easier to maneuver
News: Moderna (MRNA +$1.41 or +3.21% pre-open) announced that, in response to a prior Refusal-to-File (RTF) letter, the MRNA has engaged with the FDA in a Type A meeting and proposed a revised regulatory approach for its investigational seasonal influenza vaccine candidate, mRNA-1010. To advance the review, Moderna proposed a regulatory pathway based on age, seeking full approval for adults 50 to 64 years of age and accelerated approval for adults 65 and older, along with a post-marketing requirement to conduct an additional study in older adults.
Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.
Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!
February 15, 2026
A scorecard of covered companies
Q4/25 and FY254 net losses or incomes correlated to EPS leanings of per share value, cash positions and “runways”, financials outcomes and correlation of "street" expectations - it's a reflection of this universe's investing "status"
I have written what I as an investor would want to know …
Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
February 18, 2026
Sector share pricing explodes … with Moderna’s (MRNA +$2.67 or +6.08%) experimental mRNA flu shot; has the FDA agreeing to review flu shot, reversing the agency’s earlier decision to refuse to accept the application
Reiterating, “Have “investors” trigger a contrarian sell signal?”
RMi collects, curates, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision
Pre-open Indications: 3 Hits and 1 Miss
Never leave a retail investor uninformed! It’s not always time to buy or sell; but it is time to KNOW why!
February 15, 2026
A scorecard of covered companies Q4/25 and FY254 net losses or incomes correlated to EPS leanings of per share value, cash positions and “runways”, financials outcomes and correlation of "street" expectations - it's a reflection of this universe's investing "status" I have written what I as an investor would want to know … Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
February 4, 2026
SGMO continues to fall -$0.0168 or -4.31% to $0.37 Proceeds are estimated at $25 M SGMO closed <Monday> at $0.5679 and is trading at -$0.1413 or -24.74% to $0.44 Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering. The offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock.
January 25, 2026
AXGN closed +$0.83 or +2.59% to $32.83 with an aftermarket value of +$0.16 or +0.49% Having increased the deal from US$85 million to US$124 M, with the funds earmarked for debt repayment, working capital, and general corporate uses. The gross proceeds expected to be approximately $124 M (assuming no exercise of the underwriters’ option expecting to close on 1/23/26, subject to the satisfaction of customary closing conditions.
1 hour 28 min ago
RMi Closing Bell: Boom
10 hours 44 min ago
RMi Pre-opening: Stretched or a fetch?
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
